Skip to main content
. 2018 Apr 3;8:5498. doi: 10.1038/s41598-018-23539-4

Figure 3.

Figure 3

Effects of anti-IL-23R monoclonal antibodies on CIM. (A) Preventive treatment of WT mice with CIM with control antibodies (control) and anti-IL-23R monoclonal antibodies (anti IL-23R). The antibodies (1.0 mg/mouse) were administrated intraperitoneally a day before and 6 days after the immunization. The incidences of CIM in the two groups were 100% and 0%, respectively. (B) Therapeutic treatment of WT mice with CIM with the same dose of the antibodies 7 and 11 days after the immunization. The severity of CIM was evaluated histologically 14 days after the immunization. The incidences of CIM in the two groups were 83% and 28%, respectively. The results are representative of 2 independent experiments. Bars show the mean of the histological scores. Asterisks represent statistically significant differences (p < 0.05).